Featured Research

from universities, journals, and other organizations

PET imaging used to more accurately manage treatment, predict survival for patients with gliomas

Date:
December 3, 2012
Source:
Society of Nuclear Medicine
Summary:
In the management of gliomas -- tumors that originate in the brain -- precise assessment of tumor grade and the proliferative activity of cells plays a major role in determining the most appropriate treatment and predicting overall survival. New research highlights the potential of imaging with 3'-deoxy-3'-F-18-fluorothymidine positron emission tomography to non-invasively and accurately provide tumor-specific details to guide management of patients with gliomas.

In the management of gliomas -- or tumors that originate in the brain -- precise assessment of tumor grade and the proliferative activity of cells plays a major role in determining the most appropriate treatment and predicting overall survival. Research published in the December issue of The Journal of Nuclear Medicine (JNM) highlights the potential of imaging with 3'-deoxy-3'-F-18-fluorothymidine (F-18-FLT) positron emission tomography (PET) to noninvasively and accurately provide tumor-specific details to guide management of patients with gliomas.

Gliomas are uncommon neoplasms, and most are diffuse tumors that grow quickly. Patients with glioblastoma, the most malignant and most frequent type of glioma, typically die within two years. Ensuring the most appropriate treatment in a timely manner is of utmost importance for these patients.

Two studies in the December issue of JNM explore the utility of F-18-FLT PET for providing prognostic information for patients with gliomas."Theaccumulation of F-18-FLT is dependent on the presence of thymidine kinase-1, which is closely associated with cellular proliferation. In several clinical studies, F-18-FLT has been validated for evaluation of tumor grade and cellular proliferation in gliomas," noted Yuka Yamamoto, MD, lead author of the study,"Correlation of 18F-FLT Uptake with Tumor Grade and Ki-67 Immunohistochemistry in Patients with Newly Diagnosed and Recurrent Gliomas."

In the study led by Yamamoto, researchers retrospectively evaluated F-18-FLT uptake in patients with newly diagnosed (36 patients) and recurrent (20 patients) gliomas. Patients underwent F-18-FLT PET scans; tissue specimens were then taken to obtain a pathological diagnosis.The F-18-FLT images were analyzed by two nuclear medicine physicians, who identified tumor lesions as areas of focally increased uptake exceeding that of normal brain background, and who determined the tumor-to-normal (T/N) ratio. Results the 18-F-FLT PET scan were compared with tumor grade and proliferative activity estimated from the tissue specimens.

Researchers found that there was significant difference in the T/N ratio among different grades of newly diagnosed and recurrent gliomas. F-18-FLT uptake correlated more strongly with the proliferative activity in newly diagnosed gliomas than in recurrent gliomas and provided a more comprehensive view to determine tumor grade as compared to a single tissue specimen.

The correlation between proliferative volume and prediction of overall survival for high-grade glioma patients was also examined in the article "3'-Deoxy-3'-18F-Fluorothymidine PET-Derived Proliferative Volume Predicts Overall Survival in High-Grade Glioma Patients." In the study, 26 consecutive patients underwent preoperative 18-F-FLT PET/computed tomography (CT) scans. The maximum standardized uptake value (SUVmax) was calculated and three different PET segmentation methods were used to estimate the proliferative volume. The prognostic value of the SUVmaxand the different methods to approximate proliferative volume for overall survival were then assessed.

The mean overall survival for the patients in the study was 397 days; 19 patients died during this time. Based on this follow-up information, researchers determined that the signal-to-background ration (SBR) for an adaptive threshold delineation (PVSBR) method showed a significantly better association with overall survival then the SUVmaxor the other two PET segmentation methods.

"The predictive value of the proliferative volume for the overall survival of patients seems to be independent of the postoperative treatment," explained Albert J.S. Idema, MD, lead author of the study. "The importance for patients is the possible utilization of 18-F-FLT PET to select the most appropriate treatment options. The very limited burden that the procedure causes to the patient is a further asset."

The development of new molecular imaging agents, such as F-18-FLT, which is currently used only for research purposes, has enabled clinical researchers to utilize the agents to assess the characteristics of tumors and their therapeutic response. "We hope that these findings will be helpful for identifying the role of F-18-FLT in assessing the response to antiproliferative treatment in patients with gliomas," said Yamamoto.

Authors of the article "3'-Deoxy-3'-18F-Fluorothymidine PET-Derived Proliferative Volume Predicts Overall Survival in High-Grade Glioma Patients"include Albert J.S. Idema, Hieronymus D. Boogaarts and J. Andre Grotenhuis, Department of Neurosurgery, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Aswin L. Hoffmann and Esther G.C. Troost, Department of Radiation Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, and Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands; Pieter Wesseling, Department of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, and Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands; Arend Heerschap, Department of Radiology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Winette T.A. van der Graaf, Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; and Wim J.G. Oyen, Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

Authors of the article "Correlation of 18F-FLT Uptake with Tumor Grade and Ki-67 Immunohistochemistry in Patients with Newly Diagnosed and Recurrent Gliomas"include Yuka Yamamoto, Yuko Ono, Fumitoshi Aga, and Yoshihiro Nishiyama, Department of Radiology, Faculty of Medicine, Kagawa University, Kagawa, Japan; Nobuyuki Kawai, Department of Neurosurgery, Faculty of Medicine, Kagawa University, Kagawa, Japan; and Nobuyuki Kudomi, Department of Medical Physics, Faculty of Medicine, Kagawa University, Kagawa, Japan.


Story Source:

The above story is based on materials provided by Society of Nuclear Medicine. Note: Materials may be edited for content and length.


Journal References:

  1. Y. Yamamoto, Y. Ono, F. Aga, N. Kawai, N. Kudomi, Y. Nishiyama. Correlation of 18F-FLT Uptake with Tumor Grade and Ki-67 Immunohistochemistry in Patients with Newly Diagnosed and Recurrent Gliomas. Journal of Nuclear Medicine, 2012; 53 (12): 1911 DOI: 10.2967/jnumed.112.104729
  2. A. J. S. Idema, A. L. Hoffmann, H. D. Boogaarts, E. G. C. Troost, P. Wesseling, A. Heerschap, W. T. A. van der Graaf, J. A. Grotenhuis, W. J. G. Oyen. 3'-Deoxy-3'-18F-Fluorothymidine PET-Derived Proliferative Volume Predicts Overall Survival in High-Grade Glioma Patients. Journal of Nuclear Medicine, 2012; 53 (12): 1904 DOI: 10.2967/jnumed.112.105544

Cite This Page:

Society of Nuclear Medicine. "PET imaging used to more accurately manage treatment, predict survival for patients with gliomas." ScienceDaily. ScienceDaily, 3 December 2012. <www.sciencedaily.com/releases/2012/12/121203125328.htm>.
Society of Nuclear Medicine. (2012, December 3). PET imaging used to more accurately manage treatment, predict survival for patients with gliomas. ScienceDaily. Retrieved September 17, 2014 from www.sciencedaily.com/releases/2012/12/121203125328.htm
Society of Nuclear Medicine. "PET imaging used to more accurately manage treatment, predict survival for patients with gliomas." ScienceDaily. www.sciencedaily.com/releases/2012/12/121203125328.htm (accessed September 17, 2014).

Share This



More Health & Medicine News

Wednesday, September 17, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com
Obama Orders Military Response to Ebola

Obama Orders Military Response to Ebola

AP (Sep. 16, 2014) Calling the Ebola outbreak in West Africa a potential threat to global security, President Barack Obama is ordering 3,000 U.S. military personnel to the stricken region amid worries that the outbreak is spiraling out of control. (Sept. 16) Video provided by AP
Powered by NewsLook.com
UN: 20,000 Could Be Infected With Ebola by Year End

UN: 20,000 Could Be Infected With Ebola by Year End

AFP (Sep. 16, 2014) Nearly $1.0 billion dollars is needed to fight the Ebola outbreak raging in west Africa, the United Nations say, warning that 20,000 could be infected by year end. Duration: 00:40 Video provided by AFP
Powered by NewsLook.com
Obama: Ebola Outbreak Threat to Global Security

Obama: Ebola Outbreak Threat to Global Security

AP (Sep. 16, 2014) President Obama is ordering U.S. military personnel to West Africa to deal with the Ebola outbreak, which is he calls a potential threat to global security. (Sept. 16) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

      Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins